What treatment plan is recommended for a patient with major depressive disorder (MDD) and generalized anxiety disorder (GAD) who is taking fluoxetine 60 mg daily and aripiprazole 2 mg at bedtime, and who reports lack of motivation and anger outbursts?

Treatment Plan for MDD and GAD with Lack of Motivation and Anger Outbursts on Current Therapy

Add cognitive behavioral therapy (CBT) to the current medication regimen, as combination therapy with antidepressants shows equivalent efficacy to medication adjustments and may specifically address the residual symptoms of motivation and anger without additional medication burden 1.

Assessment of Current Treatment Response

This patient is on fluoxetine 60 mg (maximum FDA-approved dose for MDD) 2 plus low-dose aripiprazole 2 mg. The persistence of lack of motivation and anger outbursts indicates inadequate response after what should be 6-8 weeks of adequate pharmacotherapy 3. According to ACP guidelines, treatment modification is warranted when patients don't achieve adequate response within this timeframe 3.

Evidence-Based Treatment Options

Primary Recommendation: Add CBT

• Low-quality evidence shows no difference in response, remission, or depression severity between augmenting antidepressants with another medication (bupropion or buspirone) versus augmenting with cognitive therapy 1
• CBT augmentation avoids polypharmacy risks and specifically targets behavioral symptoms like motivation deficits and anger management
• The current aripiprazole dose (2 mg) is at the lower end of the therapeutic range (2-15 mg with fluoxetine) 4, but increasing it may worsen akathisia and restlessness—side effects that could exacerbate anger outbursts

Alternative Pharmacologic Strategies (if CBT unavailable or declined):

Option 1: Increase aripiprazole to 5-10 mg

• Aripiprazole augmentation has shown efficacy in treatment-resistant depression with mean MADRS score improvements of -8.8 vs -5.8 for placebo 4
• Specifically effective for MDD with anxious distress (relevant given GAD comorbidity), with significant improvements in both HAMA and HAMD scores 5
• Therapeutic range with fluoxetine is 2-15 mg; current 2 mg dose may be subtherapeutic 4
• Common side effects: akathisia (23.1%), restlessness (14.3%), headache 4—monitor closely as these could worsen anger symptoms

Option 2: Switch to or augment with bupropion

• Bupropion augmentation decreases depression severity more than buspirone and has lower discontinuation rates due to adverse events 1
• Particularly beneficial for motivation deficits due to dopaminergic/noradrenergic activity
• Lower sexual dysfunction rates than SSRIs 3
• Caution: May increase anxiety initially in some patients with GAD

Option 3: Switch to different SSRI/SNRI

• Moderate-quality evidence shows no difference in response when switching between second-generation antidepressants (bupropion vs. sertraline vs. venlafaxine) 1
• Given equivalent efficacy, switching is less compelling than augmentation strategies

Clinical Algorithm

1. Verify adequate trial: Confirm patient has been on fluoxetine 60 mg for ≥6-8 weeks 3

2. Assess specific symptom targets:

   • Lack of motivation → suggests need for dopaminergic agent (bupropion) or behavioral activation (CBT)
   • Anger outbursts → may indicate akathisia from aripiprazole, anxiety breakthrough, or irritability from depression
   • Check for akathisia/restlessness that could manifest as anger

3. First-line modification: Add CBT while continuing current medications 1

4. If pharmacologic change preferred:

   • Increase aripiprazole to 5 mg, then titrate to 10 mg over 2-4 weeks if tolerated 4
   • Monitor weekly for first month for akathisia, restlessness, and anger symptoms
   • If anger worsens or akathisia develops, consider switching to bupropion augmentation instead

5. Reassess at 6-8 weeks of modified treatment 3

Critical Monitoring Points

• Suicidality: SSRIs carry increased suicide risk, particularly in first 1-2 months; monitor closely with any treatment change 3, 2
• Akathisia: Can present as restlessness, agitation, or irritability—easily confused with anger outbursts 4
• Activation symptoms: Anxiety, nervousness, insomnia reported in 12-16% on fluoxetine 2—may contribute to anger
• Weight/appetite changes: Monitor given high-dose fluoxetine 2

Common Pitfalls to Avoid

• Don't assume anger = inadequate depression treatment: Rule out medication-induced akathisia from aripiprazole first
• Don't stack multiple augmentation agents: Evidence doesn't support triple therapy; choose one augmentation strategy
• Don't switch antidepressants prematurely: Fluoxetine is at maximum dose; augmentation is preferred over switching 1
• Don't ignore the GAD component: Anxious depression may predict higher side effect burden, particularly nervousness and agitation 6